J4

• 临床研究 • 上一篇    下一篇

恶性血液病Flt3基因内部串联重复突变分析

高素君,李 薇,杨 芳,王冠军*   

  1. 吉林大学第一医院血液肿瘤科,吉林 长春130021
  • 收稿日期:2003-08-21 修回日期:1900-01-01 出版日期:2004-07-28 发布日期:2004-07-28
  • 通讯作者: 王冠军

Analysis on Flt3 internal tandem duplicationmutation in malignant hematopoietic diseases

GAO Su-jun,LI Wei,YANG Fang,WANG Guan-jun*   

  1. Department of Hematology and Oncology, First Hospital, Jilin University, Changchun 130021, China
  • Received:2003-08-21 Revised:1900-01-01 Online:2004-07-28 Published:2004-07-28
  • Contact: WANG Guan-jun<

摘要: 目的:研究Flt3-ITD在恶性血液病中的突变及分布情况。 方法:采用PCR法检测103例恶性血液病患者基因组DNA Flt3-ITD突变。结果:44例初治急性髓细胞白血病(AML)患者中8例发生Flt3-ITD突变,突变率为18.2%,以M1型最高;急性淋巴细胞白血病(ALL)、骨髓增生异常综合征(MDS)、多发性骨髓瘤(MM)、非何杰淋巴瘤(NHL)及慢性髓细胞白血病(CML)均未检出Flt3-ITD突变。 结论:Flt3-ITD可作为AML重要分子标志。

关键词: sub>基因, 白血病, 聚合酶链反应, 突变

Abstract: Objective To investigate Flt3 tandem duplication mutation (ITD) and its distribution in different malignant hematopoietic diseases. Methods PCR was used to detect the Flt3-ITD mutation in blast cell of bone marrow from 103 patients with malignant hematopoietic disease. Results Flt3-ITD mutations were found in 18.2% (8/44)of the patients with primary acute myeloid leukemia (AML), more Flt3 aberrations were found in patients with FAB M1. Flt3-ITD mutations were not found in patients with acute lymphoid leukemia (ALL), myelodysplastic syndrome(MDS), multiple myeloma(MM), non-Hodgkin′s lymphoma(NHL), and chronic myeloid leukemia (CML). Conclusion Flt3-ITD can be a important molecular marker for AML.

Key words: sub> gene, leukemia, polymerase chain reaction, mutation

中图分类号: 

  • R773.7